DOCSLIB.ORG

NMMC West Point CDM.Xlsx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Facility Description Price CC SWING BED RUGS CODE CC PRIVATE 1ST WEST 861 CC PRIVATE OBSTETRICS 861 CC BAKRI BALLOON FOR PP HEMR 661 CC BAKRI BALLOON FOR PP HEMR 661 CC RPR CMPX LID/N/L 2.6‐7.5 1914 CC RPR CMPX LID/N/ E/A 5CM/< 1053 CC RPR CMPX LID/N/L 2.6‐7.5 1914 CC RPR CMPX LID/N/ E/A 5CM/< 1053 CC PRIVATE ECU 494 CC IV THRPY FIRST HR DX 691 CC IV THRPY EA/ADD HR DX 190 CC IV THRPY ADD/SEQ TO 1 HR 205 CC IV THRPY CONCURRENT 122 CC IV THRPY FIRST HR HYDRTN 690 CC IV THRPY EA/ADD HR HYDRTN 134 CC INJ IV EA ADD DIFF MED 269 CC RECOVERY PER HOUR 280 CC MINOR PROCEDURE 1627 CC ARTERIAL LINE PLACEMENT 463 CC INJ EPIDURAL BLOOD PATCH 2850 CC INJ IV PUSH INITIAL 692 CC ADDITIONAL CPT CODE CC MED ICU ROOM CHARGE 1872 CC NURSERY 1200 CC CIRC TRAY 91 CC INIT HOSP CARE LV 1 P/DAY 205 CC INIT HOSP CARE LV 2 P/DAY 279 CC INIT HOSP CARE LV 3 P/DAY 412 CC SUBS HOSP CARE LV 1 P/DAY 81 CC SUBS HOSP CARE LV 2 P/DAY 147 CC SUBS HOSP CARE LV 3 P/DAY 212 CC HOSP DAY MGMT 30 MNT OR < 147 CC HOSP DAY MGMT > 30 MNTS 214 CC OBS CARE D/C DAY MGMT 155 CC INITL OBS CARE LV 1 P/DAY 197 CC INITL OBS CARE LV 2 P/DAY 239 CC INITL OBS CARE LV 3 P/DAY 362 CC SUBS OBS CARE LV 1 P/DAY 88 CC SUBS OBS CARE LV 2 P/DAY 145 CC SUBS OBS CARE LV 3 P/DAY 236 CC SNF D/C DAY MGMT 30 OR < 240 CC SNF D/C DAY MGMT >30 318 CC PERC REPLAC J TUBE W/O FL 1948 CC INITIAL NF CARE LEVEL 1 204 CC INITIAL NF CARE LEVEL 2 290 CC INITIAL NF CARE LEVEL 3 368 CC SUBSQENT NF CARE LEVEL 197 CC SUBSQENT NF CARE LEVEL 2 151 CC SUBSQENT NF CARE LEVEL 3 198 CC SUBSQENT NF CARE LEVEL 4 295 CC OBS OR I/P CARE LEVEL 1 281 CC OBS OR I/P CARE LEVEL 2 365 CC OBS OR I/P CARE LEVEL 3 455 CC IP CONSULTATION LEVEL 1 103 CC IP CONSULTATION LEVEL 2 188 CC IP CONSULTATION LEVEL 3 230 CC IP CONSULTATION LEVEL 4 271 CC IP CONSULATATION LEVEL 5 312 CC CARDIOPULMONARY RESUSCIT 394 CC PHYSICIAN CRITICAL CARE 1281 CC PHYS CRIT CAR EA AD 30 MN 289 CC REPL CATH CVA SUBQ PORT 6767 CC NF D/S DAY MGMT 30 MNTS 240 CC NF D/S DAY MGMT > 30 MINS 318 CC PLACE CV CATH SUBCLV/JUG 577 CC OBSERVATION PER HOUR 56 CC DIRECT REFER OBS ASSESMT 1951 CC RECOVERY PER HOUR 62 CC BIOPSY CERVIX SINGLE 1832 CC BIOPSY VAGINAL SIMPLE 1830 CC BLADDER IRRIGATION/LAVAGE 594 CC BLOOD DRAW VAD 422 CC CATHETER, INFUSION A79 CC CHANGE CYSTOSTOMY TUBE 596 CC CHANGE GASTROSTOMY TUBE 1317 CC CULDOCNTESIS/COLPOCNTESIS 4357 CC MARSUP BARTHLIN CYST BL 6537 CC DEBRID SKIN SUB‐Q TISSUE 1236 CC APP FINGER SPLINT LT 231 CC DEBRD SKN/SUB OPN FX/DIS 1483 CC BLADDER SCAN 711 CC MOD SEDATION 1ST 15 MIN 399 CC MOD SEDATON EA/ADD 15 MNS 53 CC DILAT URETHRA,FEMALE INIT 350 CC DILT URETRAL MALE INITL 2726 CC E&M LEVEL 1 EST PATIENT 410 CC E&M LEVEL 1 EST PATIENT P 410 CC E&M LEVEL II EST PATIENT 425 CC E&M LEVEL II EST PAT P 425 CC E&M LEVEL 3 EST PATIENT 440 CC E&M LEVEL 3 EST PATIENT P 440 CC E&M LEVEL 4 EST PATIENT 460 CC E&M LEVEL 4 EST PATIENT P 460 CC E&M LEVEL 5 EST PATIENT 485 CC E&M LEVEL 5 EST PATIENT P 485 CC ENDOMTRL BX W/WO ENDOCERV 420 CC FINE NDL ASPRTION WO/IMAG 1238 CC GASTRIC INTUBATION LAVAGE 640 CC GUIDEWIRES 400 CC I&D ABCESS COMPLICATED 1236 CC I&D ABCESS SIMPLE 649 CC I&D BATHOLINS GLAND, LT 473 CC I&D BATHOLINS GLAND, RT 473 CC I&D HEMATOMA,FLUID COLL 4297 CC I&D PERIANAL ABSCESS 1652 CC I&D PERIRECTAL ABSCESS 5594 CC INCIS SOFT TISS ABSCESS 649 CC INCIS THROMBO HEMORRHOID 683 CC IV THRPY EA/ADD HR DX 202 CC IV THRPY IFRST HR DX 691 CC INJ IM OR SQ 205 CC INJ IV PUSH INITIAL 692 CC INSRT INDWL BLDR CATH CMX 468 CC INSRT INDWL BLDR CATH SIM 434 CC INSRT NON‐INDWL BLDR CATH 422 CC INTRDUCR/SHEATH NON‐LASER 719 CC MARSUP BARTHLIN CYST LT 4358 CC MARSUP BARTHLIN CYST RT 4358 CC MISC PROCEDURE CC PERITONEAL LAVAGE INITIAL 1604 CC PLACE CV CATH SUBCLV/JUG 6490 CC PLACE PICC LINE W/O PORT 8466 CC REM CTRL LINE W/O PORT 1883 CC REM FECAL IMPACTION/FB 966 CC REM IMPACTED CERUMEN 248 CC REMOVE SKIN TAG 647 CC SCREENING PAP SMEAR 33 CC SHUNTS/DRAINS CATHS A 442 CC SPINAL PUNCTURE DRAIN CSF 2646 CC SPINAL PUNCTURE LUMBAR DX 2304 CC TRACHEOSTOMY TUBE CHANGE 748 CC TX WD DEHISCENCE SIMPLE 1914 CC BONE MARROW ASPIRATION 2585 CC IV THRPY ADD/SEQ TO 1 HR 205 CC IV THRPY CONCURRENT 122 CC IV THRPY FIRST HR HYDRTN 690 CC IV THRPY EA/ADD HR HYDRTN 134 CC INJ IV EA ADD DIFF MED 288 CC INJ IV EA ADD SAME MED 246 CC BLD DRAW FROM CNTRAL LINE 422 CC IMMUNIZATION 1ST VAC 205 CC IMMUNIZATION EA ADD VAC 205 CC IRRIGATION OF A VAD 231 CC APP LONG ARM SPLINT LT 576 CC APP LONG ARM SPLINT RT 576 CC APP SHORT ARM SPLINT LT 484 CC APP SHORT ARM SPLINT RT 484 CC APP FINGER SPLINT RT 231 CC APP LONG LEG SPLINT LT 557 CC APP LONG LEG SPLINT RT 557 CC APP SHORT LEG SPLINT LT 529 CC APP SHORT LEG SPLINT RT 529 CC OTHER SPLINT 529 CC ANKLE ORTHOSIS 37 CC KO IMMOBLIZR CNVS PREFAB 67 CC POST OF SHOE 27 CC WHO COCK‐UP PREFAB 37 CC APP LONG ARM SPLINT 50 865 CC APP SHORT ARM SPLINT BL 726 CC APP FINGER SPLINT BIL 346 CC APP LONG LEG SPLINT BL 793 CC APP SHORT LEG SPLINT BL 793 CC I&D BATHOLINS GLAND BL 711 CC PARACENTESIS W/O ULTRSOND 1893 CC PARACENTESIS W/ULTRASOUND 2030 CC EX FCE LD NSE LIP 2.1‐3CM 2585 CC SELCT DEBRID 20 SQCM OR < 474 CC PT DEBRID ADD 20 SQCM 198 CC REMOVE CUFFED CHEST TUBE 2805 CC TUBE THORACOSTOMY LT 6490 CC TUBE THORACOSTOMY RT 2893 CC THORCEN INS TUBE W/O GUID 2893 CC PICC LINE REMOVAL 1883 CC DECLOT CATHETER/PORT/VAD 1181 CC EXC NAIL & MATRX PRMNT 1236 CC BX MUSCLE/SOFT TISSUE 2585 CC CHEMODENERVATION MUSCLE 776 CC INJ ANES FEMRAL NRV SINGL 1577 CC INJ FEMORAL NERVE BILAT 2366 CC CLSD TX SHOULDER DISLOCAT 4278 CC ENDOMTRL BX W/WO ENDOCERV 420 CC DESTRUCT MALIG LESN FACE 989 CC IR, MIDLINE PLACEMENT 5900 CC PERCUTANS NEEDLE BX LIVER 3937 CC INJ PLATLET RICH PLASMA 829 CC PICC LINE W/O PRT W/O IMA 4893 CC INTUBATN ENDOTRACHEL EMRG 1444 CC ADMIN INFLUENZA VACINE 61 CC ADMIN OF PNEUMONIA VACINE 61 CC MISC. PROCEDURE CC NEW PAT 20 MIN OFFICE VT 183 CC NEW PAT 30 MIN OFFICE VT 265 CC NEW PAT 45 MIN OFFICE VT 407 CC NEW PAT 60 MIN OFFICE VT 506 CC EST PAT 10 MIN OFFICE V 112 CC EST PAT 15 MIN OFFICE 5 195 CC EST PAT 25 MIN OFFICE 5 276 CC EST PAT 40 MIN OFFICE 5 370 CC NEW PAT 20 MIN OFFICE VT 183 CC NEW PAT 30 MIN OFFICE VT 265 CC NEW PAT 45 MIN OFFICE VT 407 CC NEW PAT 60 MIN OFFICE VT 506 CC EST PAT 05 MIN OFFICE VT 55 CC EST PAT 10 MIN OFFICE V 112 CC EST PAT 15 MIN OFFICE 5 195 CC EST PAT 25 MIN OFFICE 5 276 CC EST PAT 40 MIN OFFICE 5 370 CC CSDS OUTPT ROOM ZERO CHG CC CSDS OUTPT ROOM ZERO CHG 0 CC LITHO SURGERY BASE RATE 13002 CC LITHO SURGERY PER MINUTE 80 CC ORAL/DENTL SURG BASE RATE 6017 CC ORAL/DENTAL SURG PER MIN 69 CC EAR NOSE THRT SURG BASE 7520 CC ENT SURG PER MIN 69 CC OPHTHALMIC SURG BASE RATE 6017 CC OPHTHALMIC SURG PER MIN 69 CC GENERAL SURG BASE RATE 7520 CC GENERAL SURG PER MIN 69 CC ORTHOPEDIC SURG BASE RATE 9023 CC ORTHOPEDIC SURG PER MIN 69 CC PLASTIC SURG BASE RATE 6017 CC PLASTIC SURGERY PER MIN 69 CC UROLOGIC SURG, BASE RATE 8273 CC UROLOGIC SURGERY PER MIN 69 CC MISC SURGERY BASE RATE 7147 CC MISC.SURGERY PER MIN 69 CC ADDITIONAL CPT CODE CC MINOR SURGERY BASE RATE 2159 CC MINOR SURGERY PER MNT 28 CC PLAC NDL BREST 1ST SRT BL 4125 CC NDL PLCMNT BRST EA ADD ST 1376 CC CARDIOVERSION EXTERNAL 4633 CC MISC OPERATING ROOM CHRG CC ADDITIONAL CPT CODE CC ANCHOR/SCREW A 276 CC ANCHOR/SCREW B 537 CC CATH,BALON DILIT/NONVAS A 556 CC CATHTR DILYSIS/SHRT TERM 392 CC CATHETER, INFUSION A79 CC CATHETER, INFUSION B 483 CC CATHETER, INFUSION C 1179 CC CATHETER, THROM/EMBOLEC A 101 CC CATHETER, THROM/EMBOLEC B 625 CC CONNECTVE TISSUE HUMAN A 954 CC CONNECTVE TISSUE HUMAN B 1278 CC CONNECTVE TISSUE HUMAN F 3701 CC CONCTVE TISSU NON‐HUMAN A 1020 CC CONCTVE TISSU NON‐HUMAN B 1700 CC GRAFT VASCULAR D 1303 CC GRAFT VASCULAR E 1731 CC GRAFT VASCULAR F 2049 CC GUIDEWIRE A 139 CC GUIDEWIRE B 258 CC GUIDEWIRE C 420 CC HEMOSTATIC AGENT A75 CC HEMOSTATIC AGENT B 156 CC HEMOSTATIC AGENT C 354 CC HEMOSTATIC AGENT D 2031 CC IMPLNT/ENT/OPH/ORL/PLAS A 171 CC IMPLNT/ENT/OPH/ORL/PLAS B 511 CC IMPLANT/ORTHOPEDIC A 1130 CC IMPLANT/ORTHOPEDIC B 2490 CC IMPLANT/ORTHOPEDIC C 5368 CC IMPLANT/ORTHOPEDIC D 7566 CC IMPLANT/ORTHOPEDIC E 9970 CC INTRDUCR/SHETH NON‐LASR B 327 CC JOINT DEVICE SHOULDER A 18805 CC JOINT DEVICE SHOULDER B 6516 CC JOINT DEVICE SHOULDER C 8812 CC JOINT DEVICE SHOULDER D 10750 CC JOINT DEVICE SHOULDER E 15034 CC JOINT DEVICE KNEE A 1661 CC JOINT DEVICE KNEE B 4545 CC JOINT DEVICE KNEE C 7232 CC JOINT DEVICE KNEE D 9129 CC JOINT DEVICE KNEE E 11558 CC JOINT DEVICE KNEE F 13783 CC JOINT DEVICE KNEE G 16285 CC MESH IMPLANTABLE A 174 CC MESH IMPLANTABLE B 359 CC MESH IMPLANTABLE C 769 CC MESH IMPLANTABLE D 1119 CC MESH IMPLANTABLE E 1488 CC MESH IMPLANTABLE F 1942 CC PORT INDWELLING A 1054 CC PROSTHESIS BREAST A 1280 CC PROSTHESIS BREAST B 2650 CC PROSTHESIS BREAST C 3640 CC RPR DEVCE URNARY W/GRFT A 2778 CC SHNT/DRAIN/CONECTR/CATH A 159 CC SHNT/DRAIN/CONECTR/CATH B 722 CC SHNT/DRAIN/CONECTR/CATH C 1679 CC SHNT/DRAIN/CONECTR/CATH D 2556 CC STENT NON‐CORONARY TEMP A 441 CC STENT NON‐CORONARY TEMP B 558 CC CATH, ABLAT,NON‐CARDIAC 5045 CC INTRAOCULAR LENS POSTRIOR 763 CC CATH BALON DILTN/NONVAS C 1033 CC MESH IMPLANTABLE G 2508 CC MESH IMPLANTABLE H 3079 CC MESH IMPLANTABLE I 4088 CC MESH IMPLANTABLE J 4981 CC MESH, IMPLANTABLE K 7076 CC JOINT DEVICE KNEE I 21296 CC JOINT DEVICE KNEE J 23805 CC JOINT DEVICE KNEE K 26307 CC JOINT DEVICE KNEE L 28812 CC JOINT DEVICE KNEE M 31320 CC JOINT DEVICE KNEE N 33824 CC JOINT DEVICE KNEE O 36327 CC JOINT DEVICE KNEE CC HEMOSTATIC AGENT E 540 CC SURGICAL SUPPLY CC SURGICAL IMPLANT/DEVICE CC HARMONIC SCALPEL SHEARS 1311 CC DEVICE SEALER DISPSBLE A 1477 CC MESH IMPLANTABLE L 7602 CC MESH IMPLANTABLE M 9739 CC MESH IMPLANTABLE
Recommended publications
  • Optum Essential Health Benefits Enhanced Formulary PDL January

    Optum Essential Health Benefits Enhanced Formulary PDL January

    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
  • Pharmacokinetic Drug–Drug Interactions Among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients

    Pharmacokinetic Drug–Drug Interactions Among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients

    International Journal of Molecular Sciences Review Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients Marta Kara´zniewicz-Łada 1 , Anna K. Główka 2 , Aniceta A. Mikulska 1 and Franciszek K. Główka 1,* 1 Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 60-781 Pozna´n,Poland; [email protected] (M.K.-Ł.); [email protected] (A.A.M.) 2 Department of Bromatology, Poznan University of Medical Sciences, 60-354 Pozna´n,Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-(0)61-854-64-37 Abstract: Anti-epileptic drugs (AEDs) are an important group of drugs of several generations, rang- ing from the oldest phenobarbital (1912) to the most recent cenobamate (2019). Cannabidiol (CBD) is increasingly used to treat epilepsy. The outbreak of the SARS-CoV-2 pandemic in 2019 created new challenges in the effective treatment of epilepsy in COVID-19 patients. The purpose of this review is to present data from the last few years on drug–drug interactions among of AEDs, as well as AEDs with other drugs, nutrients and food. Literature data was collected mainly in PubMed, as well as google base. The most important pharmacokinetic parameters of the chosen 29 AEDs, mechanism of action and clinical application, as well as their biotransformation, are presented. We pay a special attention to the new potential interactions of the applied first-generation AEDs (carba- Citation: Kara´zniewicz-Łada,M.; mazepine, oxcarbazepine, phenytoin, phenobarbital and primidone), on decreased concentration Główka, A.K.; Mikulska, A.A.; of some medications (atazanavir and remdesivir), or their compositions (darunavir/cobicistat and Główka, F.K.
  • Chapter 25 Mechanisms of Action of Antiepileptic Drugs

    Chapter 25 Mechanisms of Action of Antiepileptic Drugs

    Chapter 25 Mechanisms of action of antiepileptic drugs GRAEME J. SILLS Department of Molecular and Clinical Pharmacology, University of Liverpool _________________________________________________________________________ Introduction The serendipitous discovery of the anticonvulsant properties of phenobarbital in 1912 marked the foundation of the modern pharmacotherapy of epilepsy. The subsequent 70 years saw the introduction of phenytoin, ethosuximide, carbamazepine, sodium valproate and a range of benzodiazepines. Collectively, these compounds have come to be regarded as the ‘established’ antiepileptic drugs (AEDs). A concerted period of development of drugs for epilepsy throughout the 1980s and 1990s has resulted (to date) in 16 new agents being licensed as add-on treatment for difficult-to-control adult and/or paediatric epilepsy, with some becoming available as monotherapy for newly diagnosed patients. Together, these have become known as the ‘modern’ AEDs. Throughout this period of unprecedented drug development, there have also been considerable advances in our understanding of how antiepileptic agents exert their effects at the cellular level. AEDs are neither preventive nor curative and are employed solely as a means of controlling symptoms (i.e. suppression of seizures). Recurrent seizure activity is the manifestation of an intermittent and excessive hyperexcitability of the nervous system and, while the pharmacological minutiae of currently marketed AEDs remain to be completely unravelled, these agents essentially redress the balance between neuronal excitation and inhibition. Three major classes of mechanism are recognised: modulation of voltage-gated ion channels; enhancement of gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission; and attenuation of glutamate-mediated excitatory neurotransmission. The principal pharmacological targets of currently available AEDs are highlighted in Table 1 and discussed further below.
  • THE CONCISE GUIDE to PHARMACOLOGY 2017/18 Alexander, Stephen P

    THE CONCISE GUIDE to PHARMACOLOGY 2017/18 Alexander, Stephen P

    University of Dundee THE CONCISE GUIDE TO PHARMACOLOGY 2017/18 Alexander, Stephen P. H.; Fabbro, Doriano; Kelly, Eamonn; Marrion, Neil V.; Peters, John A.; Faccenda, Elena Published in: British Journal of Pharmacology DOI: 10.1111/bph.13876 Publication date: 2017 Licence: CC BY Document Version Publisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA): Alexander, S. P. H., Fabbro, D., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Catalytic receptors. British Journal of Pharmacology, 174 (Suppl. 1), S225-S271. https://doi.org/10.1111/bph.13876 General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 23. Sep. 2021 S.P.H.
  • 5 Clinical Pearls for Contraception and Preconception Counseling

    5 Clinical Pearls for Contraception and Preconception Counseling

    EDITORIAL Women with epilepsy: 5 clinical pearls for contraception and preconception counseling For women with epilepsy, intrauterine devices are the optimal reversible contraceptive, and, preconception, the use of antiepileptic drugs with the lowest teratogenic potential should be considered Robert L. Barbieri, MD Editor in Chief, OBG MANAGEMENT Chair, Obstetrics and Gynecology Brigham and Women’s Hospital, Boston, Massachusetts Kate Macy Ladd Professor of Obstetrics, Gynecology and Reproductive Biology Harvard Medical School, Boston n 2015, 1.2% of the US population bazepine (Aptiom), felbamate (Fel- becoming pregnant while taking the was estimated to have active epi- batol), oxcarbazepine (Trileptal), oral contraceptive.6 Carbamazepine, Ilepsy.1 For neurologists, key goals perampanel (Fycompa), phenobarbi- a strong inducer of hepatic enzymes, in the treatment of epilepsy include: tal, phenytoin (Dilantin), primidone was the most frequently used AED in controlling seizures, minimizing (Mysoline), rufinamide (Banzel), this sample. adverse effects of antiepileptic drugs and topiramate (Topamax) (at dos- Many studies report that carba- (AEDs) and optimizing quality of ages >200 mg daily). According to mazepine accelerates the metabo- life. For obstetrician-gynecologists, Lexicomp, the following AEDs do not lisms of estrogen and progestins and women with epilepsy (WWE) have cause clinically significant changes reduces contraceptive efficacy. For unique contraceptive, preconcep- in hepatic enzymes that metabolize example, in one study 20 healthy tion, and obstetric needs that require steroid hormones: acetazolamide women were administered an ethi- highly specialized approaches to (Diamox), clonazepam (Klonopin), nyl estradiol (20 µg)-levonorgestrel care. Here, I highlight 5 care points ethosuximide (Zarontin), gabapentin (100 µg) contraceptive, and randomly that are important to keep in mind (Neurontin), lacosamide (Vimpat), assigned to either receive carbamaze- when counseling WWE.
  • Quantum of Effectiveness Evidence in FDA's Approval of Orphan Drugs

    Quantum of Effectiveness Evidence in FDA's Approval of Orphan Drugs

    Quantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs Cataloguing FDA’s Flexibility in Regulating Therapies for Persons with Rare Disorders by Frank J. Sasinowski, M.S., M.P.H., J.D.1 Chairman of the Board National Organization for Rare Disorders One of the key underlying issues facing the development of effective for their intended uses. all drugs, and particularly orphan drugs, is what kind of evi- dence the Food and Drug Administration (FDA) requires for FDA has for many decades acknowledged that there is a need approval. The Federal Food, Drug, and Cosmetic [FD&C] Act IRUÁH[LELOLW\LQDSSO\LQJLWVVWDQGDUGIRUDSSURYDO)RUH[- provides that for FDA to grant approval for a new drug, there ample, one of FDA’s regulations states that: “FDA will ap- must be “substantial evidence” of effectiveness derived from prove an application after it determines that the drug meets the “adequate and well-controlled investigations.” This language, statutory standards for safety and effectiveness… While the which dates from 1962, provides leeway for FDA medical re- statutory standards apply to all drugs, the many kinds of drugs viewers to make judgments as to what constitutes “substantial that are subject to the statutory standards and the wide range HYLGHQFHµRIDGUXJ·VHIIHFWLYHQHVVWKDWLVRILWVEHQHÀWWR RIXVHVIRUWKRVHGUXJVGHPDQGÁH[LELOLW\LQDSSO\LQJWKHVWDQ- patients. GDUGV7KXV)'$LVUHTXLUHGWRH[HUFLVHLWVVFLHQWLÀFMXGJPHQW to determine the kind and quantity of data and information an 7KHVROHODZWKDWDSSOLHVVSHFLÀFDOO\WRRUSKDQGUXJVWKH2U- applicant is required to provide for a particular drug to meet SKDQ'UXJ$FWRISURYLGHGÀQDQFLDOLQFHQWLYHVIRUGUXJ the statutory standards.” 21 C.F.R. § 314.105(c). FRPSDQLHVWRGHYHORSRUSKDQGUXJVZKLFKLVOHJDOO\GHÀQHG as products that treat diseases that affect 200,000 or fewer )'$SXEOLFO\KDVH[SUHVVHGVHQVLWLYLW\WRDSSO\LQJWKLVÁH[- patients in the U.S.
  • Drug and Medication Classification Schedule

    Drug and Medication Classification Schedule

    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
  • Monitoring and Mathematical Modeling of in Vitro Human Megakaryocyte Expansion and Maturation Dynamics

    Monitoring and Mathematical Modeling of in Vitro Human Megakaryocyte Expansion and Maturation Dynamics

    YOUNES LEYSI-DERILOU MONITORING AND MATHEMATICAL MODELING OF IN VITRO HUMAN MEGAKARYOCYTE EXPANSION AND MATURATION DYNAMICS Thèse présentée à la Faculté des études supérieures de l’Université Laval dans le cadre du programme de doctorat en génie chimique pour l’obtention du grade de Philosophiae doctor (Ph.D.) DEPARTMENT DE GÉNIE CHIMIQUE FACULTÉ DE SCIENCES ET GÉNIE UNIVERSITÉ LAVAL QUÉBEC 2011 © Younes Leysi-Derilou, 2011 ii Résumé La mégakaryopoïèse est un processus complexe, qui prend naissance à partir des cellules souches hématopoïétiques (HSC). Ces dernières se différencient par étapes successives en mégakaryocytes (MKs) qui, suite à leur maturation, libèrent les plaquettes. Afin de modéliser le sort des HSCs lors de la mégakaryopoïèse en culture, un nouveau modèle mathématique a été développé, basé sur un programme de différenciation tridimensionnelle (3-D) où chaque sous-population est représentée par un compartiment. Dans le but d’évaluer la prolifération, la différenciation des MKs immatures puis matures, la cinétique de mort cellulaire ainsi que le nombre de plaquettes produites, à partir des cellules de sang de cordon (CB) ombilical enrichies en CD34+, un ensemble d'équations différentielles a été déployé. Les cellules CD34+ ont été placées en culture dans un milieu optimisé pour la différenciation mégakaryocytaire. Les paramètres cinétiques ont été estimés pour deux températures d'incubation (37°C versus 39°C). Les résultats des régressions ont été validés par l'évaluation de l'estimabilité des paramètres, en utilisant des analyses de sensibilité locale et globale, puis la détermination d'un intervalle de confiance. Ceux-ci ont été comparés par le biais de tests statistiques et d’analyses en composante principale (ACP).
  • CDER List of Licensed Biological Products With

    CDER List of Licensed Biological Products With

    Center for Drug Evaluation and Research List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date DATE OF FIRST REFERENCE PRODUCT DATE OF LICENSURE LICENSURE EXCLUSIVITY EXPIRY DATE INTERCHANGEABLE (I)/ BLA STN PRODUCT (PROPER) NAME PROPRIETARY NAME (mo/day/yr) (mo/day/yr) (mo/day/yr) BIOSIMILAR (B) WITHDRAWN 125118 abatacept Orencia 12/23/05 NA NA 103575 abciximab ReoPro 12/22/94 NA NA Yes 125274 abobotulinumtoxinA Dysport 04/29/09 125057 adalimumab Humira 12/31/02 NA NA 761071 adalimumab-adaz Hyrimoz 10/30/18 B 761058 adalimumab-adbm Cyltezo 08/25/17 B 761118 adalimumab-afzb Abrilada 11/15/19 B 761024 adalimumab-atto Amjevita 09/23/16 B 761059 adalimumab-bwwd Hadlima 07/23/19 B 125427 ado-trastuzumab emtansine Kadcyla 02/22/13 125387 aflibercept Eylea 11/18/11 103979 agalsidase beta Fabrazyme 04/24/03 NA NA 125431 albiglutide Tanzeum 04/15/14 017835 albumin chromated CR-51 serum Chromalbin 02/23/76 103293 aldesleukin Proleukin 05/05/92 NA NA 103948 alemtuzumab Campath, Lemtrada 05/07/01 NA NA 125141 alglucosidase alfa Myozyme 04/28/06 NA NA 125291 alglucosidase alfa Lumizyme 05/24/10 125559 alirocumab Praluent 07/24/15 103172 alteplase, cathflo activase Activase 11/13/87 NA NA 103950 anakinra Kineret 11/14/01 NA NA 020304 aprotinin Trasylol 12/29/93 125513 asfotase alfa Strensiq 10/23/15 101063 asparaginase Elspar 01/10/78 NA NA 125359 asparaginase erwinia chrysanthemi Erwinaze 11/18/11 761034 atezolizumab Tecentriq 05/18/16 761049 avelumab Bavencio 03/23/17
  • Status Epilepticus

    Status Epilepticus

    Status Epilepticus By Aaron M. Cook, Pharm.D., BCPS, BCCCP Reviewed by Gretchen M. Brophy, Pharm.D., FCCP, BCPS; Matthew J. Korobey, Pharm.D. BCCCP; and You Min Sohn, Pharm.D., M.S., BCPS, BCCCP LEARNING OBJECTIVES 1. Evaluate factors that may affect treatment success in patients with status epilepticus. 2. Distinguish gaps in the literature related to optimal status epilepticus treatment. 3. Evaluate therapeutic strategies for super-refractory status epilepticus. 4. Assess the impact of timing of status epilepticus treatment initiation, and develop strategies to optimize effective treatment. DEFINITIONS OF STATUS EPILEPTICUS ABBREVIATIONS IN THIS CHAPTER Status epilepticus is defined as continuous seizure activity for EEG Electroencephalogram greater than 5 minutes or consecutive seizures without regaining GABA g-Aminobutyric acid consciousness over 5 minutes. Status epilepticus is common in ICH Intracerebral hemorrhage the epilepsy population and is often associated with acute, severe NMDA N-methyl-D-aspartate neurological injury or illness such as traumatic brain injury (TBI), TBI Traumatic brain injury intracerebral hemorrhage (ICH), meningitis, or pharmacologic toxic- Table of other common abbreviations. ity/withdrawal. Overall, the incidence of status epilepticus is about 12 per 100,000 individuals, a value that has increased 50% since the early 2000s (Dham 2014). Status epilepticus is often divided into “convulsive” status epilepticus (in which the patient has obvi- ous clinical manifestations of seizures, mental status impairment, or postictal focal neurological deficits) and “nonconvulsive” status epi- lepticus (in which the patient has no obvious clinical manifestations of seizure, but seizure activity is revealed on electroencephalogram [EEG]). Refractory status epilepticus is defined as status epilepticus that persists despite treatment with at least two antiepileptic drugs.
  • Evaluating the Effect of Oprelvekin on Cardiac Repolarization in Subjects with Chemotherapy-Induced Thrombocytopenia: an Observa

    Evaluating the Effect of Oprelvekin on Cardiac Repolarization in Subjects with Chemotherapy-Induced Thrombocytopenia: an Observa

    Journal of Case Reports and Studies Volume 5 | Issue 2 ISSN: 2348-9820 Case Report Open Access Evaluating the Effect of Oprelvekin on Cardiac Repolarization in Subjects with Chemotherapy-Induced Thrombocytopenia: An Observational Chart Review of a Phase 2 Clinical Trial in Laredo, Texas Soriano RA*1 and Gonzalez M2 1The London School of Economics and Political Science, London, UK 2Envision Clinical Research, LLC, Laredo Texas 78041, USA *Corresponding author: Soriano RA, The London School of Economics and Political Science, London, UK, E-mail: [email protected] Citation: Soriano RA, Gonzalez M (2017) Evaluating the Effect of Oprelvekin on Cardiac Repolarization in Subjects with Chemotherapy-Induced Thrombocytopenia: An Observational Chart Review of a Phase 2 Clinical Trial in Laredo, Texas. J Case Rep Stud 5(2): 204. doi: 10.15744/2348-9820.5.204 Received Date: March 05, 2017 Accepted Date: April 26, 2017 Published Date: April 28, 2017 Abstract This study tested for the cardiac effects of Oprelvekin, recombinant human interleukin-11, a thrombopoietic growth factor, in patients afflicted with chemotherapy-induced thrombocytopenia (platelet count<50,000 cells/ul). Chart-reviews of patients fulfilling the inclusion criteria of: 18-75 yrs of age, non-myeloid malignancy, with adequate hematologic, hepatic and renal parameters and normal electrocardiograms that were enrolled in this phase 2 trial were analyzed. Patients of child-bearing potential agreed to be on a reliable form of birth control for the duration of the study. Results on 4 patients suggest that Oprelvekin does not cause atrial nor ventricular arrhythmia, a rare severe cardiac side effect, in treating patients with chemotherapy-induced thrombocytopenia.
  • Standard Specialty PA and QL List January 2015

    Standard Specialty PA and QL List January 2015

    Standard Specialty PA and QL List January 2015 Standard PA or PA with QL Programs Therapeutic Category Drug Name Quantity Limit Anti-infectives Antiretrovirals, Hepatitis B BARACLUDE (entecavir) 1 tab/day BARACLUDE (entecavir) Soln 630 ml/30days HEPSERA (adefovir) 1 tab/day TYZEKA (telbivudine ) 1 tab/day Antiretrovirals, HIV FUZEON (enfuvirtide) 60 vials or 1 kit/30 days SELZENTRY (maraviroc) None TRUVADA (emtricitabine/tenofovir) None Cardiology Antilipemic JUXTAPID (lomitapide) 20 mg 3 tabs/day JUXTAPID (lomitapide) 5 mg, 10 mg 1 tab/day KYNAMRO (mipomersen) 4 syringes/28 days Pulmonary Arterial Hypertension ADCIRCA (tadalafil) 2 tabs/day ADEMPAS (riociguat) 90 tabs/30 days FLOLAN (epoprostenol) None LETAIRIS (ambrisentan) 1 tab/day OPSUMIT (macitentan) 1 tab/day ORENITRAM (treprostinil diolamine) None REMODULIN (treprostinil) None REVATIO (sildenafil) 3 tabs or vials/day TRACLEER (bosentan) 2 tabs/day TYVASO (treprostinil) 1 ampule/day VELETRI (epoprostenol) None VENTAVIS (iloprost) 9 ampules/day Vasopressors NORTHERA (droxidopa) None Central Nervous System Anticonvulsants SABRIL (vigabatrin) None Depressant XYREM (sodium oxybate) 3 bottles (540 mL)/30 days Neurotoxins BOTOX (onabotulinumtoxinA) None DYSPORT (abobotulinumtoxinA) None MYOBLOC (rimabotulinumtoxinB) None XEOMIN (incobotulinumtoxinA) None Parkinson's APOKYN (apomorphine) None Sleep Disorder HETLIOZ (tasimelteon) 1 cap/day Dermatology Alkylating Agents VALCHLOR (mechlorethamine) Gel None Endocrinology & Metabolism Gonadotropins ELIGARD (leuprolide) 22.5 mg (3-month) 1